[go: up one dir, main page]

ES2062241T3 - Metodo de purificacion de la albumina serica humana. - Google Patents

Metodo de purificacion de la albumina serica humana.

Info

Publication number
ES2062241T3
ES2062241T3 ES90117928T ES90117928T ES2062241T3 ES 2062241 T3 ES2062241 T3 ES 2062241T3 ES 90117928 T ES90117928 T ES 90117928T ES 90117928 T ES90117928 T ES 90117928T ES 2062241 T3 ES2062241 T3 ES 2062241T3
Authority
ES
Spain
Prior art keywords
purification method
human
seric albumin
albumin
human seric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90117928T
Other languages
English (en)
Inventor
Wataru C O The Green Cr Ohtani
Akinori C O The Green Cro Sumi
Takao C O The Green Cro Ohmura
Yahiro C O The Green Cr Uemura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp Japan
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17051210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2062241(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp Japan, Green Cross Corp Korea filed Critical Green Cross Corp Japan
Application granted granted Critical
Publication of ES2062241T3 publication Critical patent/ES2062241T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DICHO METODO COMPRENDE EL TRATAMIENTO POR CALOR DE LA SOLUCION QUE CONTIENE SERO ALBUMINA HUMANA A APROXIMADAMENTE 50 70 C, DURANTE 1 Y/O UN ACIDO CARBOXILICO DE UN ACIDO CARBOXILICO ORGANICO DE 6 - 12 ATOMO DE CARBONO O SAL DEL MISMO.
ES90117928T 1989-09-18 1990-09-18 Metodo de purificacion de la albumina serica humana. Expired - Lifetime ES2062241T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1239877A JPH0671434B2 (ja) 1989-09-18 1989-09-18 ヒト血清アルブミンの製造方法

Publications (1)

Publication Number Publication Date
ES2062241T3 true ES2062241T3 (es) 1994-12-16

Family

ID=17051210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90117928T Expired - Lifetime ES2062241T3 (es) 1989-09-18 1990-09-18 Metodo de purificacion de la albumina serica humana.

Country Status (8)

Country Link
US (1) US5132404A (es)
EP (1) EP0420007B1 (es)
JP (1) JPH0671434B2 (es)
KR (1) KR100199523B1 (es)
CA (1) CA2025605C (es)
DE (1) DE69005959T2 (es)
DK (1) DK0420007T3 (es)
ES (1) ES2062241T3 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0671434B2 (ja) * 1989-09-18 1994-09-14 株式会社ミドリ十字 ヒト血清アルブミンの製造方法
US5268273A (en) * 1990-12-14 1993-12-07 Phillips Petroleum Company Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
JPH0671432B2 (ja) * 1991-03-20 1994-09-14 株式会社ミドリ十字 ヒト血清アルブミンの製造方法
ES2147748T3 (es) * 1991-12-18 2000-10-01 Icu Medical Inc Valvula medica.
US5521287A (en) * 1992-05-20 1996-05-28 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
CA2138349A1 (en) * 1993-12-17 1995-06-18 Welfide Corporation Method for decoloring human serum albumin
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
ES2211889T3 (es) * 1994-08-31 2004-07-16 Mitsubishi Pharma Corporation Procedimiento para la purificacion de albumina de suero recombinante.
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
JP4798833B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
JP4798832B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
ES2261487T3 (es) * 2000-10-24 2006-11-16 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Metodo de monomerizacion de polimeros de albumina de suero humano.
JP4259324B2 (ja) * 2002-02-28 2009-04-30 ニプロ株式会社 安定化されたアルブミン製剤
DK1710250T3 (da) 2004-01-20 2009-07-06 Chemo Sero Therapeut Res Inst Fremgangsmåde til fremstilling af humanserumalbumin ved varnebehandling i tilstedeværelse af divalt kation
WO2007071068A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
EP2301561A4 (en) 2008-05-15 2012-02-29 R Tech Ueno Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYES AND / OR HORN SKIN / BINDING SKIN DISEASES
KR101568360B1 (ko) 2013-08-06 2015-11-12 이화여자대학교 산학협력단 열안정화된 인간혈청알부민의 제조방법
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
EP4267210A1 (en) 2020-12-28 2023-11-01 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2444679A (en) * 1945-11-30 1948-07-06 Arthur J Shaukis Mailbox
US2765299A (en) * 1952-06-27 1956-10-02 Armour & Co Recovery of serum albumin
US3100737A (en) * 1958-02-05 1963-08-13 Auerswald Wilhelm Method of preparing a plasma protein solution free of active hepatitis virus and product produced thereby
FR2190437B1 (es) * 1972-07-05 1975-08-08 Merieux Inst
JPS5417002B2 (es) * 1974-02-18 1979-06-27
JPS5225019A (en) * 1975-08-19 1977-02-24 New Zealand Inventions Dev Production of serum albumin
JPS5312965A (en) * 1976-07-22 1978-02-06 Tatsuo Teraoka Method of manufacture of frp
DK25877A (da) * 1977-01-21 1978-08-15 Nordisk Insulinlab Fremgangsmaade til udvinding af renset albumin fra blodplasma
JPS5417002A (en) * 1977-07-07 1979-02-08 Pioneer Electronic Corp Record player
US4426323A (en) * 1980-01-10 1984-01-17 Ionics, Incorporated Selected recovery of proteins from fermentation broths
JPS5795997A (en) * 1980-12-08 1982-06-15 Nippon Sekijiyuujishiya Removal of admixed protein from albumin-containing solution in presence of water-soluble high polymer
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4613501A (en) * 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
FR2579224B1 (fr) * 1985-03-25 1987-05-22 Genetica Procede de preparation microbiologique de la serum-albumine humaine
US4675387A (en) * 1985-07-26 1987-06-23 E. I. Du Pont De Nemours And Company Method for extracting protein with organic acid
JPS62224284A (ja) * 1986-03-25 1987-10-02 Agency Of Ind Science & Technol 微生物
GB8613388D0 (en) * 1986-06-03 1986-07-09 Delta Biotechnology Ltd Induction of galactose regulated gene expression in yeast
US4723944A (en) * 1986-06-05 1988-02-09 Jensen Ole R Fluid collection receptacle with improved non-return valve
JPS62294621A (ja) * 1986-06-13 1987-12-22 Green Cross Corp:The アルブミンの回収方法
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
GB8615701D0 (en) * 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
JPH0811074B2 (ja) * 1987-10-30 1996-02-07 財団法人化学及血清療法研究所 プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
JPH0671434B2 (ja) * 1989-09-18 1994-09-14 株式会社ミドリ十字 ヒト血清アルブミンの製造方法

Also Published As

Publication number Publication date
JPH03103188A (ja) 1991-04-30
EP0420007A1 (en) 1991-04-03
JPH0671434B2 (ja) 1994-09-14
US5132404A (en) 1992-07-21
CA2025605A1 (en) 1991-03-19
KR100199523B1 (ko) 1999-06-15
DE69005959T2 (de) 1994-06-16
CA2025605C (en) 2000-10-31
KR910006481A (ko) 1991-04-29
DK0420007T3 (da) 1994-02-21
EP0420007B1 (en) 1994-01-12
DE69005959D1 (de) 1994-02-24

Similar Documents

Publication Publication Date Title
ES2062241T3 (es) Metodo de purificacion de la albumina serica humana.
DE3587941D1 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
IT1227707B (it) Sistema di irrigazione per l'impiego durante l'artroscopia
DK0563731T3 (da) Lægemidler indeholdende polyhydromethylenderivater, fremgangsmåde til deres fremstilling og deres anvendelse
FR2633929B2 (fr) Derives non toxiques de l'acide n-butyrique, presentant des actions therapeutiques retardees
GR3005398T3 (es)
ZA883599B (en) Mixed crystals of insulin and insulin derivatives,a process for the preparation of these mixed crystals,pharmaceutical agents containing these mixed crystals,and the use thereof for the treatment of diabetes mellitus
MY104006A (en) 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases.
PH24139A (en) Method of treating anxiety with tetrahydrobenzy(c,d)indole-6-carboxamides
EP0515434A4 (en) Method for treating intestinal diseases
PH24568A (en) Use of bezafibrate for treating diabetes
ZA904671B (en) Hair treatment composition
ATE48595T1 (de) Verfahren zur rueckgewinnung von 4,4'dihydroxydiphenylsulfonaus einer isomermischung.
GR3006674T3 (es)
DE3467340D1 (en) Process for purification of 1,2-unsaturated carboxylic acids and/or esters thereof
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
ATE67931T1 (de) Butylhydroxyanisole zur behandlung von retrovirus-krankheiten.
FR2723105B1 (fr) Procede biologique d'elimination des traces dihalgenoacides, des solutions aqueuses d'amino-acides
GR77250B (es)
DK417889A (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.
FR2621039B1 (fr) Derives non toxiques de l'acide n-butyrique, presentant des actions therapeutiques retardees
IT8722869V0 (it) Dispositivo perfezionato per l'abbronzatura artificiale integrale o parziale.
RO92448A2 (ro) Metoda de tratament chirurgical al ulcerului cu bont duodenal dificil

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 420007

Country of ref document: ES